man. Diabetologia 1985;28:412â419. 24. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;.
ORIGINAL ARTICLE
METABOLIC SYNDROME AND RELATED DISORDERS Volume X, Number X, 2015 Mary Ann Liebert, Inc. Pp. 1–7 DOI: 10.1089/met.2015.0053
A Larger Body Mass Index is Associated with Increased Atherogenic Dyslipidemia, Insulin Resistance, and Low-Grade Inflammation in Individuals with Metabolic Syndrome Kolin Ebron, MS,1 Catherine J. Andersen, PhD,1,2 David Aguilar, PhD,1 Christopher N. Blesso, PhD,1 Jacqueline Barona, PhD,1,3 Christine E. Dugan, PhD,1 Jennifer L. Jones, PhD,1 Taif Al-Sarraj, PhD,1 and Maria Luz Fernandez, PhD1
Abstract
Background: The consequences of increased body mass index (BMI) on the metabolic disorders associated with metabolic syndrome (MetS) have not been thoroughly examined. Methods: We analyzed data from 262 individuals, 97 men and 165 women (aged 18–70 years), classified with MetS to investigate whether variations in BMI could be associated with parameters of dyslipidemia, insulin resistance, or low-grade inflammation. We hypothesized that increases in BMI would positively correlate with the major dysregulations in metabolism that define MetS. For this purpose, individuals were separated into four subgroups based on their BMI: normal weight (
